Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade

Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade

Background Stimulation of 4-1BB with agonistic antibodies is a promising strategy for improving the therapeutic efficacy of immune checkpoint inhibitors (ICIs) or for overcoming resistance to ICIs. However, dose-dependent hepatotoxicity was observed in clinical trials with monoclonal anti-4-1BB agon...

Full description

Bibliographic Details
Main Authors: Lei Fang, Wenqing Jiang, Zhengyi Wang, Su-Hyung Park, Eui-Cheol Shin, Minwoo Jeon, Jaeho Jung, Hyunjoo Kim, Hyung-Don Kim, Shin Hwang, Seongju Jeong, Eunyoung Park, Eunsil Sung, Jaehyoung Jeon, Youngkwang Kim, Ui-jung Jung, Yong-Gyu Son, Youngeun Hong, Hanbyul Lee, Shinai Lee, Yangmi Lim, Jonghwa Won
Format: Article
Language:English
Published: BMJ Publishing Group 2021-07-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/7/e002428.full

Internet

https://jitc.bmj.com/content/9/7/e002428.full

Similar Items